By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Rasagiline

Rasagiline

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|630 words

Rasagiline Drug Profile

What is Rasagiline?

Rasagiline is a prescription medication that belongs to a class of drugs called monoamine oxidase type B (MAO-B) inhibitors. It is primarily used to treat Parkinson’s disease, either as a standalone treatment in early-stage disease or in combination with other medications like levodopa in more advanced stages. This oral medication helps improve motor symptoms and can reduce fluctuations in movement control.

Uses

  • Early Parkinson’s disease: Used as initial therapy to help control tremor, rigidity, and bradykinesia (slowness of movement) when symptoms are mild to moderate
  • Advanced Parkinson’s disease: Added to levodopa therapy to help reduce “off” periods when medication effects wear off between doses
  • Motor fluctuation management: Helps smooth out the ups and downs in movement control that occur as Parkinson’s disease progresses
  • Neuroprotection: May potentially slow the progression of Parkinson’s disease, though this benefit is still being studied
  • Dyskinesia reduction: Can help decrease abnormal involuntary movements that sometimes develop with long-term levodopa use

How it works

Rasagiline works by blocking the enzyme monoamine oxidase type B (MAO-B), which is responsible for breaking down dopamine in the brain. By inhibiting this enzyme, rasagiline helps preserve dopamine levels in brain areas affected by Parkinson’s disease. This increased dopamine availability helps improve the communication between nerve cells that control movement and coordination.

Side effects

Common side effects:

  • Headache
  • Joint pain or arthralgia
  • Indigestion or dyspepsia
  • Depression or mood changes
  • Fall or accidental injury
  • Flu-like symptoms
  • Conjunctivitis (pink eye)
  • Dry mouth

Serious side effects requiring immediate medical attention:

Submit Your Paper
GMJ_Submit_Banner
  • Severe high blood pressure (hypertensive crisis)
  • Hallucinations or psychotic episodes
  • Sudden onset of sleep or sleep attacks
  • Severe skin reactions including melanoma
  • Signs of serotonin syndrome (confusion, fever, rapid heart rate)

Warnings and precautions

  • Tyramine-rich foods: Patients should avoid foods high in tyramine (aged cheeses, cured meats, fermented products) as they can cause dangerous blood pressure spikes when combined with rasagiline
  • Liver impairment: Dosage reduction is required in patients with mild liver problems, and the medication should not be used in moderate to severe liver disease
  • Pregnancy and breastfeeding: Safety has not been established in pregnant or nursing women, and the medication should only be used if potential benefits outweigh risks
  • Skin cancer monitoring: Regular skin examinations are recommended as Parkinson’s patients may have increased melanoma risk
  • Mental health effects: Can worsen depression or cause hallucinations, particularly in elderly patients or those with existing psychiatric conditions

Interactions

  • Antidepressants: Dangerous interactions with SSRIs, SNRIs, tricyclics, and MAO inhibitors can cause serotonin syndrome
  • Meperidine (pethidine): Can cause severe reactions including coma and should be completely avoided
  • Dextromethorphan: Found in cough medicines, can cause psychosis and bizarre behavior when combined with rasagiline
  • St. John’s Wort: This herbal supplement can increase serotonin levels and cause dangerous interactions
  • Sympathomimetics: Decongestants and stimulants can cause severe blood pressure increases
  • Ciprofloxacin: This antibiotic significantly increases rasagiline blood levels and requires dose adjustment
  • Tyramine-containing foods: Aged cheeses, wine, and fermented foods can cause hypertensive crisis
  • Other MAO inhibitors: Combining with other MAO inhibitors can cause severe and potentially fatal reactions

Check interactions with the GMJ Interaction Checker

Dosage

The typical adult dosage of rasagiline is 1 mg taken once daily, with or without food. For patients taking certain medications like ciprofloxacin or those with mild liver impairment, the dose is reduced to 0.5 mg once daily. When used alongside levodopa, the same 1 mg daily dose is usually maintained. The medication should be taken at the same time each day for optimal effectiveness. Dosage adjustments should always be made under the guidance of a healthcare provider who can monitor for effectiveness and side effects.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Rasagiline." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/rasagiline/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

DNA Test Could Spare 6,600 Breast Cancer Patients From Unnecessary Chemotherapy

New genetic testing could spare 6,600 UK breast cancer patients annually from…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Lamotrigine

By
Prof. Giorgi Pkhakadze
02/06/2026

Febuxostat

By
Prof. Giorgi Pkhakadze
02/06/2026

Valacyclovir

By
Prof. Giorgi Pkhakadze
02/06/2026

Oxcarbazepine

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up